Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Tuesday announced results from part 1 of ARC-10, evaluating the effects of the combination of Domvanalimab and Zimberelimab versus Zimberelimab or ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's third quarter ...

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

The Minister of Energy and Natural Resources, the Honourable Jonathan Wilkinson, will be participating at the EnergyNL Student Energy Day. Date: Wednesday, November 6, 2024 Time: 11 a.m. NT Minister ...

The Protein Sequencing Companytm, today announced that it will be participating in two upcoming investment conferences. Jeff Hawkins, Quantum-Si's Chief Executive Officer, ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Ophthalmic immune-related adverse events may point to a higher mortality risk in patients undergoing cancer treatment.